Aditya Bagrodia

And where do you like to see their testosterone levels kind of level out?

Yeah.

Yeah.

Yeah.

doing this halfway thing is not really you know constructive yeah i mean it used to be like less than 50 then less than 20 then it's basically undetectable and i think you kind of hit the nail on the head and you know there's been just a explosion of medications really trying to eradicate any testosterone from any source you know beyond just the hypothalamic pituitary testis access

doing this halfway thing is not really you know constructive yeah i mean it used to be like less than 50 then less than 20 then it's basically undetectable and i think you kind of hit the nail on the head and you know there's been just a explosion of medications really trying to eradicate any testosterone from any source you know beyond just the hypothalamic pituitary testis access

doing this halfway thing is not really you know constructive yeah i mean it used to be like less than 50 then less than 20 then it's basically undetectable and i think you kind of hit the nail on the head and you know there's been just a explosion of medications really trying to eradicate any testosterone from any source you know beyond just the hypothalamic pituitary testis access

And it kind of segues into, so, you know, maybe for finite favorable risk, of course, there's a counseling and it's kind of like, I just got to get through this and you'll be fine. For the higher risk, it's a longer duration. Maybe some of the metabolic elements become a little bit more front and center. And then there's kind of you're in the long haul and, you know, whether that's going to be.

And it kind of segues into, so, you know, maybe for finite favorable risk, of course, there's a counseling and it's kind of like, I just got to get through this and you'll be fine. For the higher risk, it's a longer duration. Maybe some of the metabolic elements become a little bit more front and center. And then there's kind of you're in the long haul and, you know, whether that's going to be.

And it kind of segues into, so, you know, maybe for finite favorable risk, of course, there's a counseling and it's kind of like, I just got to get through this and you'll be fine. For the higher risk, it's a longer duration. Maybe some of the metabolic elements become a little bit more front and center. And then there's kind of you're in the long haul and, you know, whether that's going to be.

intermittent or continuous as very person-specific, disease state-specific, whether they're sensitive or resistant. But just talk a little bit about maybe how you think about continuous versus intermittent ADT when appropriate.

intermittent or continuous as very person-specific, disease state-specific, whether they're sensitive or resistant. But just talk a little bit about maybe how you think about continuous versus intermittent ADT when appropriate.

intermittent or continuous as very person-specific, disease state-specific, whether they're sensitive or resistant. But just talk a little bit about maybe how you think about continuous versus intermittent ADT when appropriate.

And intermittent, so you've got them on your ADT du jour, their cast rate, their PSA is undetectable, and then you decide to give them a little bit of a holiday. Can you talk a little bit about the triggers to get them back on treatment? Are they PSAs? Are they doubling time? Are they patient anxieties or provider anxiety? What does that kind of look like?

And intermittent, so you've got them on your ADT du jour, their cast rate, their PSA is undetectable, and then you decide to give them a little bit of a holiday. Can you talk a little bit about the triggers to get them back on treatment? Are they PSAs? Are they doubling time? Are they patient anxieties or provider anxiety? What does that kind of look like?

And intermittent, so you've got them on your ADT du jour, their cast rate, their PSA is undetectable, and then you decide to give them a little bit of a holiday. Can you talk a little bit about the triggers to get them back on treatment? Are they PSAs? Are they doubling time? Are they patient anxieties or provider anxiety? What does that kind of look like?

Yeah, I couldn't agree more. I mean, there's people that really get taken for a ride with ADT. There's people that it's not so noticed. There's people that really are upset with PSA levels at various thresholds, and there's people that are not. So I agree, it's individualized.

Yeah, I couldn't agree more. I mean, there's people that really get taken for a ride with ADT. There's people that it's not so noticed. There's people that really are upset with PSA levels at various thresholds, and there's people that are not. So I agree, it's individualized.

Yeah, I couldn't agree more. I mean, there's people that really get taken for a ride with ADT. There's people that it's not so noticed. There's people that really are upset with PSA levels at various thresholds, and there's people that are not. So I agree, it's individualized.

And like you said, you know, earlier PSMA PET scanning has kind of flipped everything on its head when it comes to detecting METs. Well, you know, I think this is a topic that can be reviewed enough.